


Data Sheet

Product Name:	Droxidopa
Cat. No.:	HY-13458
CAS No.:	23651-95-8
Molecular Formula:	C ₉ H ₁₁ NO ₅
Molecular Weight:	213.19
Target:	Others
Pathway:	Others
Solubility:	DMSO: 1.8 mg/mL (Need ultrasonic and warming)



BIOLOGICAL ACTIVITY:

Droxidopa(L-DOPS, SM5688) is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); capable of crossing the protective blood-brain barrier

IC50 value:

Target:

The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow [1]. L-threo-dihydroxyphenylserine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline [2].

References:

[1]. Coll M, et al. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. *Hepatology*. 2012 Nov;56(5):1849-60.

[2]. Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. *Clin Auton Res*. 2008 Mar;18 Suppl 1:25-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA